The Coalition for Epidemic Preparedness and Innovations: a global partnership

Frederik Kristensen MD, MBA, MPH
Deputy CEO, CEPI
October 30, 2018
Overview

• About CEPI
• Our priorities and investments
• Further areas of collaboration
What is CEPI?

- Launch: Davos World Economic Forum 2017
- Global coalition of public, private, philanthropic and civil society organisations
- To stimulate, finance and coordinate vaccine development for emerging infectious diseases
- Identify priority threats and act when market forces fail to drive needed development
- Move vaccine candidates through late preclinical studies to proof of concept and safety in humans
- Build capabilities for rapid response to unknown threats
CEPI: vision, mission, strategic objectives

**Vision**
A world in which epidemics are no longer a threat to humanity

**Mission**
CEPI accelerates the development of vaccines against emerging infectious diseases and enables equitable access to these vaccines for affected populations during outbreaks

**Strategic objectives**

- **Preparedness**
  Advance access to safe and effective vaccines against emerging infectious diseases

- **Response**
  Accelerate the research, development and use of vaccines during outbreaks

- **Sustainability**
  Create durable and equitable solutions for outbreak response capacity
How CEPI works

The Board → Investors

Affected countries → Scientific Advisory committee

Joint coordinating group

CEPI

Partners
CEPI’s initial priority pathogens

- MERS
- Lassa
- Nipah
- Disease X
Just in case vaccine: MERS, Lassa, Nipah

- More than 30 proposals received in first call for proposals

- Applications from:
  - Academic institutions, biotechs, large pharmaceutical companies, and Product Development Partnerships
  - Broad diversity in vaccine platform technologies
  - Proposals from North America, Europe, Africa, Middle East, South East Asia and Australia

- Rigorous process of selection, involving:
  - An objective review of proposals by experts and our Scientific Advisory Committee
  - Rigorous budget challenge and negotiation of the agreements to meet CEPI’s budget, governance, and equitable access requirement
Seven partnership agreements signed

<table>
<thead>
<tr>
<th>Disease</th>
<th>Investment (up to)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lassa and MERS</td>
<td>$37.5 M</td>
</tr>
<tr>
<td>Lassa and MERS</td>
<td>$56.0</td>
</tr>
<tr>
<td>Lassa</td>
<td>$54.9 M</td>
</tr>
<tr>
<td>Nipah</td>
<td>$25.0 M</td>
</tr>
<tr>
<td>Lassa</td>
<td>$36.0 M</td>
</tr>
<tr>
<td>MERS</td>
<td>$36.0 M</td>
</tr>
<tr>
<td>Lassa, MERS, and Nipah</td>
<td>$19.0 M</td>
</tr>
</tbody>
</table>
CEPI priority pathogen portfolio

CEPI funds late preclinical through phase II S&I and investigational stockpile generation

- **IAVI**
  - rVSVΔG
- **Profectus**
  - rVSVNC4ΔG
  - Measles vector
- **Themis**
  - Measles vector
- **Themis**
  - Measles vector
- **Profectus**
  - Subunit
- **Oxford Janssen**
  - Adeno*
  - Adeno*

**Under contract negotiation**

- Lassa
- Nipah
- MERS CoV

* Investment in preclinical
Just in time vaccines: platform technologies

CEPI supports development of vaccine platform technologies that can be rapidly deployed against known and newly emerging pathogens, to limit or prevent future outbreaks.

Projects must demonstrate:

- Safety and immunogenicity

- Validation of the platform using 3 pathogens
  - 2 with known correlates of protection & validated animal model;
  - 1 from the WHO priority pathogen list

- Manufacturing performance
  - 16 weeks for development of vaccine candidate for a new pathogen
  - 6 weeks to clinical benefit after 1st dose
  - 8 weeks to produce 100,000 doses after go-decision

- Funding decisions to be announced Q4, 2018
Sustainable manufacturing

• Task force to analyse and propose solutions for sustainable manufacturing of EID vaccines

• The solution will be fully integrated and address the end-to-end supply chain to make vaccines available to affected populations, at an affordable price, when needed

• Look at both manufacturing technologies and economic and structural attributes to sustain the solution over time

• DCVMN will have a role to play — Atin Tomar is DCVMN representative in the working group